Analysis of Immunoglobulin Gene Rearrangement: Comparison between BIOMED-2 Multiplex PCR and Conventional Nested PCR.
- Author:
Ji Youn SUNG
1
;
So Young KANG
;
Sun Hee KIM
;
Ji Eun KWON
;
Young Hyeh KO
Author Information
- Publication Type:Original Article
- Keywords: Gene Rearrangement; Genes; Immunoglobulin; Hematologic Neoplasms; BIOMED-2
- MeSH: Gene Rearrangement; Genes, Immunoglobulin; Hematologic Neoplasms; Humans; Immunoglobulins; Light; Lymph Nodes; Lymphoma; Multiplex Polymerase Chain Reaction; Polymerase Chain Reaction; Sensitivity and Specificity
- From:Laboratory Medicine Online 2011;1(4):195-201
- CountryRepublic of Korea
- Language:Korean
- Abstract: BACKGROUND: Immunoglobulin (Ig) gene rearrangement analysis is a useful additional tool to detect clonality of B-lymphoproliferative disease and the method to detect immunoglobulin gene rearrangement is required the high sensitivity and specificity. BIOMED-2 multiplex PCR was designed for the evaluation of molecular clonality of lymphoid lesions. We evaluated the usefulness of the BIOMED-2 multiplex PCR by comparing it with conventional nested PCR. METHODS: Sixteen patients with malignant lymphoma and 5 with reactive lymph nodes were examined to assess the sensitivity, specificity, and accuracy between conventional nested PCR and BIOMED-2. All 3 tests performed using the BIOMED-2 kit for immunoglobulin (Ig) heavy chain (IGH) gene, Igkappa light chain (IGK) gene, and Iglambda light chain (IGL) gene, were used to analyze clonality. RESULTS: Both the methods showed 100% specificity (95% confidence interval, 56.6-100.0). The combination of IGH and IGK BIOMED-2 tests with or without IGL revealed the highest sensitivity (87.5%; range, 64.0-96.5%) and accuracy (90%; range, 0.70-0.97). Compared to the conventional method, the BIOMED-2 test for IGH showed a higher sensitivity (62.5%; range, 38.6-81.5%) and accuracy (71%, 0.50-0.86). CONCLUSIONS: These results suggest that, compared to the conventional method, BIOMED-2 has higher sensitivity and allows for easier interpretation while evaluating the clonality of B-lymphoproliferative disease.
